Çiǧdem Atay, Serkan Uǧurlu, Nesrin Özören
J Clin Invest.
2009;
119(3):445–447
doi:10.1172/JCI38681
This article Copyright © 2009, The American Society for Clinical Investigation
Abstract
|
Full text
|
PDF
T
he targeting of tumors is made possible through establishing protein signatures
specific for each cancer type. The recent recognition of the higher expression levels
of HSP90 and its accumulation in tumor cell mitochondria has made the HSP90 network a
feasible target for neutralization. HSP90 antagonizes the mitochondrial permeability
transition, blocking cytochrome c release and apoptosis. In this
issue of the JCI, Kang et al. report the synthesis of Gamitrinibs,
which target mitochondrially localized HSP90, specifically killing human cancer cell
lines, and provide a fresh approach for cancer treatment (see the related article
beginning on page 454).
This file is in Adobe Acrobat (PDF) format.
If you have not installed and configured the Adobe Acrobat Reader on your system.
Having trouble reading a PDF?
PDFs are designed to be printed out and read, but if you prefer to read them online, you may find it easier if you increase the view size to 125%.
Having trouble saving a PDF?
Many versions of the free Acrobat Reader do not
allow Save. You must instead save the PDF from the JCI Online page you downloaded it from. PC users:
Right-click on the Download link and choose the option that says something like "Save Link As...".
Mac users should hold the mouse button down on the link to get these same options.
Having trouble printing a PDF?
- Try printing one page at a time or to a newer printer.
- Try saving the file to disk before printing rather than opening it "on the fly." This requires that you
configure your browser to "Save" rather than "Launch Application" for the file type "application/pdf", and can
usually be done in the "Helper Applications" options.
- Make sure you are using the latest version of Adobe's Acrobat Reader.
